Zydus Pharmaceuticals
Zydus Pharmaceuticals, a prominent player in the global pharmaceutical industry, is headquartered in the United States, with significant operations across North America, Europe, and Asia. Founded in 1995, the company has established itself as a leader in the development and manufacturing of generic and specialty pharmaceuticals, focusing on areas such as oncology, cardiovascular health, and diabetes management. Zydus Pharmaceuticals is renowned for its commitment to quality and innovation, offering a diverse portfolio of products that includes injectables, biosimilars, and over-the-counter medications. The company has achieved notable milestones, including numerous FDA approvals and a strong presence in the biosimilars market, positioning it as a trusted name in healthcare. With a dedication to improving patient outcomes, Zydus continues to expand its reach and impact within the pharmaceutical landscape.
DitchCarbon Score
How does Zydus Pharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Zydus Pharmaceuticals's score of 46 is higher than 65% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Zydus Pharmaceuticals, headquartered in the US, currently does not have specific carbon emissions data available for the most recent year. The company is a current subsidiary of Zydus Lifesciences Limited, which may influence its climate commitments and emissions reporting. As of now, Zydus Pharmaceuticals has not outlined any specific reduction targets or initiatives. The absence of documented emissions data and reduction commitments suggests that the company may still be in the early stages of developing its climate strategy. Given its affiliation with Zydus Lifesciences Limited, any potential climate initiatives or emissions data may be cascaded from this parent organisation. However, without explicit targets or achievements reported, it remains unclear how Zydus Pharmaceuticals plans to address its carbon footprint or contribute to broader climate goals. In summary, Zydus Pharmaceuticals is currently lacking specific emissions data and reduction initiatives, with potential climate commitments being influenced by its parent company, Zydus Lifesciences Limited.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|
| Scope 1 | 92,070,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 168,794,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | 0,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Zydus Pharmaceuticals is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
